spacer
home > pmps > spring 2018 > traceable and transparent
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Traceable and Transparent

Theft and counterfeiting are two of the greatest issues threatening the pharmaceutical industry today, with claims that dangerous counterfeit drugs represent 10-30% of drugs available in developing countries, according to the WHO (1). Further research also estimates the cost of pharmaceutical theft to shippers and transporters alone at $30 billion a year, with an average of $4 million per loss. A deficit clearly needs to be resolved.

The supply chain of the average pharmaceutical product, from creation to delivery, is also continuing to expand geographically, as well as the number of companies involved in the chain itself. Pharma companies are relying on more and more partners to enable each stage of production and delivery to be as effective as possible and cater to new demands in the market, which, in turn, is increasing the complexity of the supply chain. A variety of additional forces are creating further complexities and will require companies reassess their strategies moving forward (2).

More diverse product types and therapies with shorter lifecycles mean the storage and delivery of certain drugs have also been transformed. New methods have been integrated for assessing, approving, and monitoring medicines, which is impacting how transparent each company has to be in terms of the supply chain. Finally, greater public scrutiny in the sector as well as tougher environmental controls and regulations are affecting the manner in which companies bring products to market.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Julie Hurley, Global Director for Enterprise Solutions at Unisys, has an extensive pharma and life sciences background, with almost 20 years’ consulting to major pharma, biotechnology, and devices organisations in areas of strategic planning, industry best practice and implementation planning. She holds a patent, Genomic Sequencing for Clinical Trials, and has published several white papers, advertorials, and points of view.
spacer
Julie Hurley
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine

VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ -- TheVax Genetics Vaccine CO., Ltd (6567.TWO) and Biotechpharma UAB have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Medical Device USA 2018

11-12 July 2018, Minneapolis, Minnesota

6th Outsourcing in Clinical Trials conference is the only clinical outsourcing platform for medical device companies within Medical Alley this year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement